PARP inhibitors plus ARSI in first-line mCRPC—a treatment for all patients?
at (code pays fourni par la source)
0 citations
memo - Magazine of European Medical Oncology
Ercan Müldür
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
19Publications signalées
802Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, OutcomesProtein Degradation and InhibitorsCancer Treatment and PharmacologyCancer Immunotherapy and Biomarkers
Les publications récentes
High mortality in patients with active malignancy and severe COVID-19
Simon Udovica, Nino Müser, Agnes Pechlaner, Andreas Reichinger et autres
at (code pays fourni par la source)
3 citations
memo - Magazine of European Medical Oncology
Practice-changing strategies in the treatment of esophageal cancer
at (code pays fourni par la source)
1 citation
memo - Magazine of European Medical Oncology
Four lines of immunochemotherapy combinations in a young patient with an aggressive metastatic colorectal cancer
Frédéric H. Witte, Wolfgang Hilbe, Ercan Müldür
at (code pays fourni par la source)
1 citation
memo - Magazine of European Medical Oncology
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson, Albert Oriol, Meral Beksaç, Anna Marina Liberati et autres
us, es, tr, it, no, gb, de, ca, fr, jp, ie, nl, pl, ru, ch, gr (code pays fourni par la source)
388 citations
The Lancet Oncology
The path of an esophageal carcinoma patient from curative to palliative treatment
Ercan Müldür, Karl Mayrhofer, Wolfgang Hilbe
at (code pays fourni par la source)
1 citation
memo - Magazine of European Medical Oncology
High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma
Arnold Bolomsky, Wolfgang Hübl, Stefano Spada, Ercan Müldür et autres
at, it, us (code pays fourni par la source)
0 citations
Clinical Lymphoma Myeloma & Leukemia
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
Arnold Bolomsky, Wolfgang Hübl, Stefano Spada, Ercan Müldür et autres
at, it, gb (code pays fourni par la source)
15 citations
American Journal of Hematology
Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?
at (code pays fourni par la source)
0 citations
memo - Magazine of European Medical Oncology
Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study
Heinz Ludwig, Elisabeth Rauch, Thomas Kuehr, Zdeněk Adam et autres
at, cz, de (code pays fourni par la source)
1 citation
Blood
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study
Heinz Ludwig, Elisabeth Rauch, Thomas Kuehr, Zdeněk Adam et autres
at, cz, de (code pays fourni par la source)
29 citations
Haematologica
Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma
Johanna Gebhart, Klaus Lechner, Cathrin Skrabs, Thamer Sliwa et autres
at, gr (code pays fourni par la source)
25 citations
Thrombosis Research
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.